newsfilter
← Latest News
GlobeNewswire·

MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia

  • The Phase 2 ZEPHYR trial for ML-007C-MA in acute schizophrenia exacerbation met its primary endpoint, with the 210/3 mg BID dose showing a statistically significant improvement in PANSS total score versus placebo at Week 5 (effect size 0.37, p=0.015).
  • Participants with baseline cognitive impairment demonstrated significant cognitive improvement on a prespecified secondary endpoint (effect size 0.51, p=0.041) independent of antipsychotic symptom changes.
  • The 210/3 mg BID dose achieved significance on key secondary endpoints including CGI-S (effect size 0.48, p=0.002) \& PANSS Positive Marder Factor (effect size 0.39, p=0.012).
  • The 330/6 mg once-daily dose showed numerical improvement but did not achieve statistical significance on the primary endpoint, though it separated on several secondary measures.
  • ML-007C-MA was well tolerated with no serious or drug-related severe adverse events, low gastrointestinal discontinuation rates (2.0%), \& no clinically meaningful signals for urinary retention, metabolic issues, or extrapyramidal symptoms.
  • MapLight plans to engage the FDA at an End-of-Phase 2 meeting to discuss the design of a registrational Phase 3 trial to confirm the 210/3 mg BID results.
  • The company is initiating planning for a separate confirmatory trial evaluating the BID dose \& alternative regimens, while the ongoing VISTA trial for Alzheimer's disease psychosis is expected to report topline results in late 2027.
  • A live webcast to discuss these results was scheduled for July 27, 2026, at 8:00 AM ET.